Avidity Biosciences (NASDAQ: RNA)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.800 | -0.710 | 0.0900 | ||||
REV | 1.900M | 1.795M | -105.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Avidity Biosciences (NASDAQ: RNA) through any online brokerage.
Other companies in Avidity Biosciences’s space includes: Replimune Group (NASDAQ:REPL), AnaptysBio (NASDAQ:ANAB), TG Therapeutics (NASDAQ:TGTX), Sangamo Therapeutics (NASDAQ:SGMO) and Kiniksa Pharmaceuticals (NASDAQ:KNSA).
The latest price target for Avidity Biosciences (NASDAQ: RNA) was reported by Credit Suisse on Wednesday, May 11, 2022. The analyst firm set a price target for 32.00 expecting RNA to rise to within 12 months (a possible 119.93% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Avidity Biosciences (NASDAQ: RNA) is $14.55 last updated June 27, 2022, 8:00 PM UTC.
There are no upcoming dividends for Avidity Biosciences.
Avidity Biosciences’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Avidity Biosciences.
Avidity Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.